- Home
- EMCG vs NTRB Comparison
EMCG vs NTRB Comparison
Compare EMCG & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- NTRB
- Stock Information
- Founded
- EMCG 2021
- NTRB 2016
- Country
- EMCG United States
- NTRB United States
- Employees
- EMCG N/A
- NTRB N/A
- Industry
- EMCG
- NTRB Industrial Specialties
- Sector
- EMCG
- NTRB Health Care
- Exchange
- EMCG NYSE
- NTRB Nasdaq
- Market Cap
- EMCG 83.7M
- NTRB 77.9M
- IPO Year
- EMCG 2022
- NTRB N/A
- Fundamental
- Price
- EMCG $11.60
- NTRB $6.17
- Analyst Decision
- EMCG
- NTRB
- Analyst Count
- EMCG 0
- NTRB 0
- Target Price
- EMCG N/A
- NTRB N/A
- AVG Volume (30 Days)
- EMCG 3.2K
- NTRB 28.2K
- Earning Date
- EMCG 01-01-0001
- NTRB 12-11-2024
- Dividend Yield
- EMCG N/A
- NTRB N/A
- EPS Growth
- EMCG 186.72
- NTRB N/A
- EPS
- EMCG 0.24
- NTRB N/A
- Revenue
- EMCG N/A
- NTRB $1,803,816.00
- Revenue This Year
- EMCG N/A
- NTRB N/A
- Revenue Next Year
- EMCG N/A
- NTRB N/A
- P/E Ratio
- EMCG $48.18
- NTRB N/A
- Revenue Growth
- EMCG N/A
- NTRB N/A
- 52 Week Low
- EMCG $10.84
- NTRB $1.93
- 52 Week High
- EMCG $13.39
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- EMCG 73.32
- NTRB 50.57
- Support Level
- EMCG $11.47
- NTRB $5.24
- Resistance Level
- EMCG $11.62
- NTRB $6.40
- Average True Range (ATR)
- EMCG 0.01
- NTRB 0.71
- MACD
- EMCG 0.01
- NTRB -0.12
- Stochastic Oscillator
- EMCG 84.62
- NTRB 33.23
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.